7 results about "Enterobacteriaceae bacterium" patented technology

Provided is a method for detecting the presence or absence and / or amount of Enterobacteriaceae bacteria in a food or drink sample, an environmental sample, or a biological sample, in a short period of time, easily and efficiently. The method includes a step of simultaneously detecting the presence or absence and / or amount of at least two or more different genera of Enterobacteriaceae bacteria in a sample based on an antigen-antibody reaction.

This invention relates to the field of high-throughput targeted sequencing technology, and particularly to a primer set and its applications for detecting important drug resistance and virulence genes in multidrug-resistant pathogens. Specifically, it includes primers for detecting various drug-resistant bacteria, such as third-generation cephalosporin-resistant Enterobacteriaceae, carbapenem-resistant Enterobacteriaceae, carbapenem-resistant Acinetobacter baumannii, and rifampicin-resistant Mycobacterium tuberculosis. This invention offers advantages such as speed, efficiency, strong targeting, and high specificity. It is suitable for analyzing the prevalence and differential distribution of multiple important drug resistance and virulence genes carried in metagenomic samples from various environments or pathogenic materials, and can be used to assess the risk of related environments, further guiding preventative and clinical treatment medications.

The invention discloses a carbapenem drug resistance gene detection primer group based on multiple PCR-time-of-flight mass spectrometry, a detection kit and a kit using method, and through a large number of screening and verification experiments, a multiple primer group suitable for time-of-flight mass spectrometry detection is obtained. Therefore, the multi-PCR-time-of-flight mass spectrometry detection of the multi-drug-resistant genes of carbapenem-resistant enterobacteriaceae bacteria becomes possible. The detection kit prepared by adopting the primer group can be used for simultaneously detecting and identifying 10 common carbapenem drug-resistant genes, including klebsiella pneumoniae KPC gene, NDM gene, IMP gene, VIM gene and OXA gene, acinetobacter baumannii OXA gene, NDM gene, Escherichia coli OXA gene, IMP gene and serratia marcescens VIM gene. Meanwhile, the kit is high in sensitivity and specificity, dozens of times of detection can be carried out in the same batch, so that the detection efficiency is greatly improved, and the kit is suitable for rapid screening and genetic typing of carbapenem drug-resistant bacteria in clinical samples.

The invention relates to a method for the fermentative production of recombinant proteins using fnr mutants of E. coli. Using these strains, increased amounts of recombinant protein in the culture medium can be achieved compared to the prior art.

The purpose of the present invention is to provide a method for producing an animal model infected with Enterobacteriaceae bacteria such as pathogenic Escherichia coli. Provided is a method for producing an animal model infected with Enterobacteriaceae bacteria, the method comprising step (1) and step (2) in the following order. (1) A step for administering a β-lactam antibacterial agent to a non-human mammal; (2) a step including the following steps (2-1) and (2-2) in random order; (2-1) a step for administering at least one selected from the group consisting of lincomycin antibacterial agents and macrolide antibacterial agents to the non-human mammal; and (2-2) a step for administering Enterobacteriaceae bacteria to the non-human mammal

The present invention relates to antibiotic-resistant bacteria, and to the prevention or treatment of infections of drug-resistant pathogens, such as carbapenem-resistant Enterobacteriaceae (CRE) and / or vancomycin-resistant Enterococcus (VRE). In particular, the invention relates to the treatment or prevention of colonisation of CRE and / or VRE in the gastrointestinal (GI) tract, before they cause invasive infections, for example in the blood. The invention provides novel formulations, pharmaceutical compositions and methods of using them to prevent or treat CRE and / or VRE infections or intestinal colonisations thereof.

Antibiotic resistance leads to deadly hospital-acquired infections globally. The World Health Organization (WHO) and the Centers for Disease Control and Prevention (CDC) have identified priority bacteria, including Methicillin-resistant Staphylococcus aureus, Pseudomonas aeruginosa, Acinetobacter baumannii, and particularly those carbapenem- resistant strains, also found in Enterobacterales (CRE) such as Escherichia coli and Klebsiella, as requiring new antibiotics. The present disclosure provides a chemical class of drugs less susceptible to existing mechanisms of antibiotic resistance and targeting difficult-to-treat bacterial infections. It more particularly provides compounds of formula (I), and compositions and uses thereof.